最新临床试验：Durvalumab和Tremelimumab治疗复发性Ⅳ期肺癌(肺-MAP治疗试验)

This phase II Lung-MAP trial studies how well durvalumab and tremelimumab works in treating patients with stage IV lung cancer that has come back after previous treatment. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

这个II期肺-MAP试验研究Durvalumab和Tremelimumab在治疗IV期复发性肺癌患者中的作用如何。单克隆抗体的免疫疗法，如durvalumab与tremelimumab，可以帮助身体的免疫系统攻击癌症，并可能干扰肿瘤细胞的生长和传播能力。

新PD-1/L1抑制剂Durvalumab ，商品名:Imfinzi ，德瓦鲁单抗；药品适应症:治疗晚期或转移性尿路上皮癌 ；适用癌种: 肺癌、尿路上皮癌、头颈部、胃癌、胰腺癌等。Tremelimumab(原名ticilimumab,CP-675206)是一个抗CTLA-4单克隆抗体。